Skip to main content

Table 1 Allele frequency distribution of the COMT V158M polymorphism in the Australian and Polish HNPCC MMR mutation positive patients

From: The Association of the COMT V158M Polymorphism with Endometrial/Ovarian Cancer in HNPCC Families Adhering to the Amsterdam Criteria

Group Population Val/Val (%) Val/Met (%) Met/Met (%) n Pearson's Chi-squared
subject group Australia 53 (26.9) 108 (54.8) 36 (18.3) 197 p = 0.02
  Poland 33 (24.6) 59 (44.0) 42 (31.3) 134  
hMLH1 mutation carriers Australia 31 (28.7) 59 (54.6) 18 (16.7) 108 p = 0.03
  Poland 17 (23.0) 32 (43.2) 25 (33.8) 74  
hMSH2 mutation carriers Australia 22 (24.7) 49 (55.1) 18 (20.2) 89 p = 0.41
  Poland 16 (26.7) 27 (45.0) 17 (28.3) 60  
mutation type: truncation/deletion Australia 50 (28.2) 95 (53.7) 32 (18.1) 177 p = 0.05
  Poland 26 (24.1) 49 (45.4) 33 (30.6) 108  
mutation type: missense Australia 3 (15.0) 13 (65.0) 4 (20.0) 20 p = 0.20
  Poland 7 (26.9) 10 (38.5) 9 (30.6) 26  
affected with CRC Australia 24 (25.5) 51 (54.3) 19 (20.2) 94 p = 0.88
  Poland 14 (25.5) 28 (50.9) 13 (23.6) 55  
unaffected with CRC Australia 28 (28.3) 53 (53.5) 18 (18.2) 99 p = 0.02
  Poland 19 (24.1) 31 (39.2) 29 (36.7) 79  
unaffected with CRC (>45 years) Australia 10 (23.3) 24 (55.8) 9 (20.9) 43 p = 0.84
  Poland 5 (22.7) 11 (50) 6 (27.2) 22  
endometrial/ovarian cancer Australia 6 (26.1) 14 (60.9) 3 (13.0) 23 p = 0.12
  Poland 5 (35.7) 4 (28.6) 5 (35.7) 14  
affected with CRC and unaffected Australia 22 (22.7) 57 (58.8) 18 (18.6) 97 p = 0.09
with endometrial/ovarian cancer Poland* 28 (23.3) 55 (45.8) 37 (30.8) 120  
  1. *This group contained males and females. The sex was unknown for all of the patients.